+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to clarify how sleep hygiene relates to the development of sarcopenia muscle loss and cognitive dysfunction in patients with chronic obstructive pulmonary disease COPD or idiopathic pulmonary fibrosis IPF. It focuses on measuring sleep time, arousal, and sleep quality to understand their effects on disease progression and life expectancy in these patients. Sleep-related disorders like insomnia and sleep apnea are common in COPD and IPF and may contribute to daytime sleepiness, reduced daily activities, depression, and cognitive issues. The study observes patients with COPD or IPF without providing any specific treatment or intervention. Researchers will monitor participants sleep patterns, including sleep time and sleep efficiency, as well as arousal during sleep. These indicators will be used to explore their relationship with the onset of sarcopenia and mild cognitive impairment over a two-year period. The study also examines how these sleep factors relate to hospitalizations and mortality from disease exacerbations. Participants will undergo assessments at enrollment and during follow-up to measure sleep quality, muscle strength, walking speed, skeletal muscle mass, and cognitive function. Researchers will track changes in these areas and record hospitalizations and deaths related to COPD or IPF exacerbations over two years. The main outcome is the link between sleep time at enrollment and the development of sarcopenia during follow-up, with secondary outcomes including cognitive impairment and other health changes. The study includes close monitoring but does not involve experimental treatments.

Age: 20Years +All Genders
1 location
E

Actively Recruiting

Researchers are evaluating whether the medicine BI 1291583 can help adults and adolescents aged 12 to under 18 who have bronchiectasis and experience flare-ups, also called exacerbations. This Phase III randomized, double-blind, placebo-controlled study aims to assess the medicines safety, tolerability, and effect on reducing flare-ups in people with this condition. Participants are randomly assigned to one of two groups. One group takes BI 1291583 tablets, and the other takes placebo tablets that look the same but contain no active medicine. They take one tablet daily for up to 76 weeks, or about 1 year and 6 months. The study includes up to 10 in-person visits and around 13 phone calls with study staff during this time. During the study, participants regularly complete a symptom diary on a smartphone about their bronchiectasis. Study doctors monitor participants health, check for flare-ups, and record any unwanted effects. The main outcome measured is the annual rate of pulmonary exacerbations up to week 76, with other assessments including lung function tests and quality of life questionnaires. Participants stay in the study for up to 1 year and 8 months in total.

Age: 12Years +All GendersPhase 3
478 locations